Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Reviews on iron, NAD+ homeostasis and use of single-cell technologies to map the immune system as well as Year in Review commentaries on single-cell technologies, development and regeneration, diabetic kidney disease, artificial intelligence and acute kidney injury in 2019.
Image: In-depth fluorescence imaging of renal blood vessels in a mouse kidney, achieved by kidney perfusion with lectin-dye conjugates before optically clearing the tissue for deep-tissue microscopy. The rainbow colours represent the blood vessels and glomeruli at different focal depths. Cover image supplied by Chih-Yung (Daniel) Lin in the SunJin Lab and Shiue-Cheng (Tony) Tang at the Department of Medical Science, National Tsing Hua University, Taiwan. Cover design: Lara Crow.
After nearly two decades, a new therapeutic agent, canagliflozin, received regulatory approval to prevent loss of kidney function, end-stage kidney disease, hospitalization for heart failure and cardiovascular death in patients with diabetic kidney disease. Nonetheless, the residual risk of kidney disease progression and complications remains high, underlining the importance of ongoing therapeutic development.
Acute kidney injury (AKI) is an important clinical problem that is associated with adverse short- and long-term outcomes. Studies published in 2019 provide new insights into the staging, risk stratification and subphenotyping of AKI as well as the adverse effects of AKI on the heart.
Artificial intelligence is increasingly being used to improve diagnosis and prognostication for acute and chronic kidney diseases. Studies with this objective published in 2019 relied on a variety of available data sources, including electronic health records, intraoperative physiological signals, kidney ultrasound imaging, and digitized biopsy specimens.
Single-cell genomics provide a powerful approach to investigate the intrinsic complexity of the kidney and understand the diverse cell types and states that exist during kidney development, homeostasis and disease. Several advances were made in 2019 that enhance our understanding of kidney immune cell states in health and disease and the quality of current kidney organoid model systems for studying human diseases.
2019 saw advances in the generation of induced pluripotent stem cell (iPSC)-derived nephron progenitors and in our understanding of how nephrons form in a kidney organoid. Fundamental studies of regeneration in zebrafish continue to provide vital clues as to how we might use iPSC-derived cells to regenerate a human nephron in vivo.
Iron is essential for life but must be strictly regulated to avoid harmful effects. The authors discuss new insights into systemic and cellular iron handling with respect to renal physiology and pathology, current treatment practices and novel therapies for kidney disease.
Here, the authors discuss evidence for a role of NAD+ imbalance in the pathogenesis of acute kidney injury (AKI) and chronic kidney disease (CKD). They suggest that disruption of NAD+ metabolism may contribute to mechanistic links among AKI, CKD and ageing.
In this Review, Stewart and colleagues describe how single-cell technologies, in particular single-cell RNA sequencing, can be used to map the complex immune landscape within organs, and how such technologies might provide insights into the role of the immune system in kidney health and disease pathogenesis.